# Ultragenyx Pharmaceutical Inc. (RARE): Dividend & Fundamentals

> Markdown mirror of https://www.dividenddata.com/stocks/rare for AI agents. Same live data as the HTML page, regenerated on the same refresh cycle. Not investment advice.

- Sector: Healthcare · Industry: Biotechnology
- Exchange: NASDAQ · Trading currency: USD

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffe...

## Quote & Key Metrics

As of 2026-10-23:

| Metric | Value |
|---|---|
| Price | $15.65 USD |
| Market Cap | $1.54B |
| P/E (TTM) | — |
| EPS (TTM) | −$5.84 |
| 52-Week Range | $12.73 – $39.89 |
| Dividend Yield (TTM) | — |

## Dividend

RARE has no dividend payment history in our records.

## Frequently Asked Questions

### What does Ultragenyx Pharmaceutical Inc. do?

Ultragenyx Pharmaceutical Inc. (RARE) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

### What is RARE's market cap?

Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalization of approximately $1.54 billion, as of October 23, 2026, based on the most recent share price and shares outstanding.

### Does RARE pay a dividend?

No, Ultragenyx Pharmaceutical Inc. (RARE) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

### Is RARE profitable?

Ultragenyx Pharmaceutical Inc. (RARE) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

### Has RARE ever paid a dividend?

No. Dividend Data's records show no dividend payments from Ultragenyx Pharmaceutical Inc. (RARE). A first dividend would appear on the Dividend tab once it is declared.

## More on Dividend Data

- Overview (HTML): https://www.dividenddata.com/stocks/rare
- Dividend history & safety: https://www.dividenddata.com/stocks/rare/dividend
- Earnings & EPS: https://www.dividenddata.com/stocks/rare/earnings
- Financial statements: https://www.dividenddata.com/stocks/rare/financials/income
- Valuation multiples: https://www.dividenddata.com/stocks/rare/valuation
- Peer comparison: https://www.dividenddata.com/stocks/rare/peers

Data sourced from primary filings and market data providers; see https://www.dividenddata.com/methodology.